TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06843967: A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,295,910

Rescue Site Savings

+$863,940

Unlock Full NCT06843967 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06843967 Rescue Dossier →